Survey: New NMIBC treatments face slow uptake
RCT compares platinum/5-FU, platinum/paclitaxel in high-risk penile cancer
FDA updates in urology: May 2025
NIAGARA: ctDNA analysis highlights durvalumab’s impact in MIBC
